High Fosfomycin Susceptibility in Escherichia Coli Recovered from Urine in Brazil

Research Article

Austin J Microbiol. 2024; 9(1): 1046.

High Fosfomycin Susceptibility in Escherichia Coli Recovered from Urine in Brazil

Fernanda Fernandes dos Santos1; Uile Paranhos5#, Tiago Barcelos Valiatti1,2; André Valêncio1; Yohanna Carvalho dos Santos Aoun Chikhani1; Carlos Alberto Franchi Júnior3; Adilson Aderito da Silva4; Ághata Cardoso da Silva Ribeiro1#

1Escola Paulista de Medicina, Universidade Federal de São Paulo – UNIFESP, São Paulo – SP, Brazil

2Faculdade de Educação de Jaru - Fimca-Jaru, Jaru – RO, Brazil

3Instituição Moura Lacerda, Ribeirão Preto – SP, Brazil

4Centro de Ciências Sociais e Aplicadas, Universidade Presbiteriana Mackenzie, São Paulo - SP, Brazil

*Corresponding author: Ághata Cardoso da Silva Ribeiro Escola Paulista de Medicina, Universidade Federal de São Paulo – UNIFESP, São Paulo – SP, Brazil. Email: aghata.cardoso@unifesp.br

Received: December 12, 2023 Accepted: January 27, 2024 Published: February 03, 2024

Abstract

Urinary Tract Infections (UTIs) are widespread globally, with a notably higher incidence in women. In 2018, the European Medicines Agency (EMA) endorsed the use of fluoroquinolones for uncomplicated UTI treatment. Following this recommendation, several international agencies adopted similar guidelines. Consequently, older antimicrobial agents like fosfomycin emerged as primary treatment options for UTIs. In this context, our study aimed to evaluate the susceptibility of Escherichia coli strains from urine samples to various recommended UTI antibiotics. These strains were collected between January 2017 and July 2020 in São Paulo, Brazil. We utilized the disk-diffusion method for antimicrobial susceptibility testing, interpreting the results according to BRCAST/EUCAST guidelines. Out of the 86,957 urine cultures undertaken during this timeframe, 10,041 yielded E. coli isolates. Of these, 8,655 were tested against fosfomycin, with 99.0% (8,572 strains) found to be susceptible. Additionally, susceptibility rates for other drugs were as follows: nitrofurantoin (95.8%), amoxicillin/clavulanic acid (83.9%), ciprofloxacin (65.1%), norfloxacin (65.6%), and levofloxacin (67.7%). Notably, of the 571 ESBL-positive strains, 94.0% were susceptible to fosfomycin. It’s important to mention a slight decline in fosfomycin susceptibility observed during this period. This finding underscores the importance of continuous monitoring for fosfomycin resistance and rational usage of the drug.

Keywords: Urinary tract infection; Fosfomycin; Fluoroquinolones; Escherichia coli.

Introduction

Urinary Tract Infections (UTIs) represent one of the most prevalent infections globally, impacting approximately 150 million individuals annually [4,20]. These infections can be anatomically categorized into lower (bladder, ureters, and urethra) and upper (kidneys) tracts. Additionally, UTIs can be defined based on symptomatic presence (symptomatic vs. asymptomatic) and the severity of the disease (complicated vs. uncomplicated). Symptomatic UTIs typically manifest with malaise, dysuria, increased urinary frequency, lumbar discomfort, and fever [2,18]. Women are more predisposed to UTIs, a susceptibility attributed to specific anatomical features of the genito-urinary tract. Factors like a shorter urethra and its proximity to the anus enhance the likelihood of urinary tract colonization by gastrointestinal microorganisms. Research indicates that 20-48% of women will experience a UTI at least once in their lives [10]. Of this cohort, 24% are anticipated to contract another UTI within the subsequent six months, with 2-5% presenting recurrent infections [3]. UTIs significantly affect morbidity; symptoms persist for an average of 6.1 days, leading to approximately 2.4 days of restricted activity and 0.4 days bedridden [18].

Bacteria, predominantly Escherichia coli, are the primary etiological agents behind UTIs (accounting for nearly 80% of cases) [6,7,14]. For years, fluoroquinolones were the preferred treatment for UTIs. However, growing concerns over bacterial resistance and documented adverse reactions led to recommendations against its use for uncomplicated UTIs, prompting the emergence of alternative therapeutic guidelines [1,5]. Fosfomycin-trometamol now stands as the primary recommendation for treating uncomplicated UTIs [3]. Fosfomycin impedes bacterial cell wall synthesis by irreversibly binding to the MurA enzyme, critical for generating bacterial cell wall components [9,12]. Given the evolving UTI treatment landscape and the surge in fosfomycin prescriptions, it's noteworthy that resistance rates to this drug in E. coli remain notably low [13,17,19]. Given these developments, it's imperative to conduct epidemiological studies detailing E. coli susceptibility to fosfomycin. This research seeks to elucidate the susceptibility patterns of E. coli strains obtained from urinary cultures associated with UTIs in São Paulo from January 2017 to July 2020.

Materials and Methods

Collection of Isolates

Urine samples were obtained from outpatients at a clinical laboratory located in the northwest region of São Paulo state. Between January 2017 and July 2020, a total of 86,957 urine cultures were carried out using CPS chromogenic agar. Subsequent bacterial identification was achieved through biochemical testing methods.

Antimicrobial Susceptibility Testing

The antimicrobial susceptibility of the isolates was determined using the Kirby-Bauer disk-diffusion method, according to the guidelines set by BRCAST (BRCAST, 2020). In brief, an inoculum standardized to 0.5 McFarland was swabbed onto the surface of Mueller-Hinton (MH) agar. Disks of different antimicrobial agents were then applied. The presence of the Extended Spectrum Beta-Lactamases (ESBL) phenotype was verified via the disk-approximation test. This utilized disks of ceftazidime, ceftriaxone, cefepime, cefotaxime, and amoxicillin/clavulanic acid. The formation of a "ghost-zone" was indicative of a confirmed ESBL phenotype (EUCAST, 2017).

Statistical Analysis

To evaluate the trend in antimicrobial susceptibility of the isolates over the 43-month period, time series analysis employing a linear regression model was used. The normality of each model was tested. Furthermore, a multinomial logistic regression was executed to compare the susceptibility rates among isolates for various agents: fosfomycin, ciprofloxacin, levofloxacin, norfloxacin, nitrofurantoin, and amoxicillin/clavulanic acid. All statistical analyses were conducted using Jamovi 1.8 software. For these analyses, a 95% confidence interval was established, and p-values of 0.05 or lower were deemed statistically significant.

Results

Out of the 86,957 urine cultures conducted, 10,041 E. coli clinical isolates were identified. Of these, 8,655 were assessed for susceptibility to fosfomycin, with 99.0% (8,572 isolates) showing susceptibility. The susceptibility rates for other tested antimicrobials, such as nitrofurantoin, amoxicillin/clavulanic acid, ciprofloxacin, norfloxacin, and levofloxacin, were 95.8%, 83.9%, 65.1%, 65.6%, and 65.7%, respectively, as visualized in Figure 1. Table 1 enumerates the susceptibility percentages for all the antimicrobials examined. Intriguingly, out of the 571 E. coli isolates identified as ESBL-positive, a notable 94.0% were susceptible to fosfomycin.